Health Care Providers' Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar.

Providers experienced an increased workload and reported less satisfaction with the biosimilar following the transition. Experiences may be improved by ensuring training for the device, a high-quality patient support program, and functioning authorization processes throughout the transition.